Orthofix Medical Inc. (OFIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

36.24-0.11 (-0.30%)

At close: 4:00PM EDT

36.24 0.00 (0.00%)
After hours: 04:04PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Triple Moving Average Crossover

View all chart patterns

Performance Outlook

Previous Close	36.35
Open	36.93
Bid	36.00 x 800
Ask	36.30 x 800
Day's Range	36.22 - 37.03
52 Week Range	30.59 - 48.50
Volume	48,174
Avg. Volume	85,309

Market Cap	713.743M
Beta (5Y Monthly)	1.14
PE Ratio (TTM)	N/A
EPS (TTM)	-0.42
Earnings Date	Nov 03, 2021 - Nov 08, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	54.38

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-54% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for OFIX

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Orthofix Medical Inc.
OFIX: Lowering target price to $49.00ORTHOFIX MEDICAL INC has an Investment Rating of BUY; a target price of $49.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
Rating
Fair Value
Economic Moat
10 days agoArgus Research

All

News

Press Releases

Research Reports

MarketWatch
Medical device maker Orthofix warns that Q3 revenue will rise only in low-single digits as COVID delays procedures
Orthofix Medical Inc. said Wednesday it expects third-quarter revenue growth to come in at a low single-digit increase over the year-earlier period, hurt by the high volume of elective procedures that have been deferred or rescheduled in the U.S. and overseas because of the recent surge in cases of COVID-19 spurred by the highly transmissible delta variant. The Lewisville, Texas-based medical device maker said it remains confident in its strategy and ability to accelerate growth over time. The c
Business Wire
Orthofix Provides Business Update
LEWISVILLE, Texas, September 29, 2021--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today provided a business update. The Company has experienced the impact of higher than expected volumes of deferred or rescheduled elective procedures resulting from hospital procedural restrictions, both in the U.S. and internationally, associated with the recent surge in COVID-19 Delta variant cases. As a result, the Company expects revenue growth for
Zacks
Orthofix (OFIX) Reaches Milestone for M6-C Disc Implants
Orthofix (OFIX) reveals that more than 60,000 M6-C artificial cervical discs have been implanted worldwide.